Description: TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. It is also developing Taigexyn for treating community-acquired pneumonia and diabetic foot infection, as well as other bacterial infections; Burixafor, a stem cell mobilizer for stem cell transplantation and chemosenzitization; TG-1000, an influenza antiviral drug for treating influenza A, B, and avian influenza H7N9; and Furaprevir, a hepatitis C virus protease inhibitor for the treatment of chronic hepatitis C. The company was founded in 2001 and is based in Taipei City, Taiwan.
Home Page: www.taigenbiotech.com.tw
No. 138, Xinming Road
Taipei,
11470
Taiwan
Phone:
886 2 8177 7020
Officers
| Name | Title |
|---|---|
| Dr. Ming-Chu Hsu Ph.D. | Founder & Director |
| Mr. Kuo-Lung Huang | Chairman, CEO, Pres & Chief Commercial Officer in Asia |
| Mr. Richard Lu | VP of Fin. |
| Dr. Peter W. Tsao M.B.A., Ph.D., MBA | VP Corp. Devel. |
| Dr. Chi-Hsin King Ph.D. | Sr. VP of Research |
Exchange: TWO
Country: TW : Taiwan
Currency: New Taiwan Dollar (NT$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 13.9815 |
| Price-to-Book MRQ: | 11.511 |
| Price-to-Sales TTM: | 369.9882 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |